But camizestrant’s use could depend on uptake of monitoring – for now.

Any hopes of differentiation could come down to side effects.

Crunch time approaches for UroGen.

Conference activity picks up, with the big one – ASCO – at the end of the month.

Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.

The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.

Giredestrant will soon become the first oral SERD to yield first-line data.

But this adds another complexity, and has camizestrant really scored a first-line win?

Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.

In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.